Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance

Journal of Clinical Psychopharmacology

Volumn 19, Issue 2, 1999, Pages 177-182

  Maes, Michael ^a,b,d   Libbrecht, Isabelle ^a   Van Hunsel, Fran ^a   Campens, Dirk ^c   Meltzer, Herbert Y ^b  

^a Clinical Research Center for Mental Health of Antwerp   (Belgium)

^b VANDERBILT UNIVERSITY   (United States)

^c Organon   (Belgium)

^d UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; FLUOXETINE; MIANSERIN; PINDOLOL; SEROTONIN ANTAGONIST;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; ILLNESS BEHAVIOR; NEUROTRANSMISSION; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECEPTOR BLOCKING; SEROTONIN UPTAKE; TRANQUILIZING ACTIVITY; TREATMENT OUTCOME;

ADULT; AGED; ANALYSIS OF VARIANCE; DEPRESSIVE DISORDER; FLUOXETINE; HUMANS; MIANSERIN; MIDDLE AGED; PINDOLOL; PSYCHIATRIC STATUS RATING SCALES;

EID: 0032905345     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199904000-00014     Document Type: Article

References (36)

1. Maes M, Meltzer HYM. The serotonin hypothesis of major depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology, the fourth generation of progress. New York: Raven Press, 1995: 933-44.
2. Maes M, Van Gastel A, Delmeire L, Meltzer HY. Decreased platelet alpha-2 adrenoceptor density in major depression: effects of tricyclic antidepressants and fluoxetine. Biol Psychiatry 1999 (in press).
3. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994;51:248-51.
4. Blier P, Bergeron R. Effectiveness of pindolol with selected anti-depressant drugs in the treatment of major depression. J Clin Psychopharmacol 1995;15:217-22.
5. Maes M, Vandoolaeghe E, Desnyder R. Efficacy of treatment with trazodone in combination with pindolol and fluoxetine in major depression. J Affect Disord 1996;17:201-10.
6. Tome MB, Isaac MT, Harte R, Holland C. Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol 1997;12:81-9.
7. Perez V, Gilaberte I, Faries D, Alvarez E, Artigas F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997;349: 1594-7.
8. Lauritzen L, Clemmesen L, Klysner R, Loldrup D, Lunde M, Schaumburg E, Waarst S, Bech P. Combined treatment with imipramine and mianserin. Pharmacopsychiatry 1992;25:182-6.
9. Pinder RM. Adrenoceptor interactions of the enantiomers and metabolites of mianserin: are they responsible for the antidepressant effect? Acta Psychiatr Scand 1985;72:1-9.
10. Wiech NL, Ursillo RC. Acceleration of desipramine-induced decrease of rat corticocerebral β-adrenergic receptors by yohimbine. Commun Psychopharmacol 1980;4:95-100.
11. Scott JA, Crews FT. Rapid decrease in rat brain β-adrenergic receptor binding during combined antidepressant α2-antagonist treatment. J Pharmacol Exp Ther 1983;224:640-6.
12. Kendall DA, Duman R, Slopis J, Enna SJ. Influence of adrenocorticotropic hormone and yohimbine and antidepressant-induced declines in rat brain neurotransmitter receptor binding and function. J Pharmacol Exp Ther 1982;222:566-71.
13. Lafon-Lopez L, Lauzel JP, Cousin R, Tapie M, Gamier JP, Tremine T. Etude de la potentialisation de deux antidepresseurs entre eux. Inf Psychiatr 1986;62:1147-58.
14. Thase ME, Rush AJ. Treatment-resistant depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology, the fourth generation of progress. New York: Raven Press, 1995:1081-98.
15. Tanum LH. Combination treatment with antidepressants in refractory depression. Int Clin Psychopharmacol 1994;9:37-40.
16. Spitzer RL, Williams JBW, Gibbon M, First MB. Structured clinical interview according to DSM-III-R. New York: American Press, 1990.
17. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatr 1960;23:56-61.
18. Burke MJ, Preskorn SH. Short-term treatment of mood disorders with standard antidepressants. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology, the fourth generation of progress. New York: Raven Press, 1995:1053-65.
19. Howell DC. Multiple comparisons among treatment means. In: Howell DC, ed. Statistical methods for psychology. Boston: Duxbury Press, 1982:289-307.
20. Berman RM, Darnell AM, Miller HL, Anand A, Charney DS. Effects of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 1997;154:37-43.
21. Zanardi R, Artigas F, Franchini L, Sforzini L, Gasperini M, Smeraldi E, Perez J. How long should pindolol be associated with paroxetine to improve the antidepressive response? J Clin Psychopharmacol 1997;17:446-50.
22. Dam J, Ryde L, Svejso J, Lauge N, Lauritsen B, Been P. Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression. Pharmacopsychiatry 1998;31:48-54.
23. Leonard BE. Some effects of mianserin on monoamine metabolism in the rat brain. Br J Clin Pharmacol 1978;5[suppl 1]:11S-12S.
24. Shader RI, Fogelman SM, Greenblatt DJ. Newer antidepressants: hypotheses and evidence. J Clin Psychopharmacol 1997;17:1-3.
25. Nalepa I, Chalecka-Franaszek E, Vetulani J. Modulation by mianserin pretreatment of the chronic electroconvulsive shock effects on the adrenergic system in the cerebral cortex of the rat. Hum Psychopharmacol 1996;11:273-82.
26. Byerley WF, McConnell EJ, McCabe RL, Dawson TM, Grosser BI, Wamsley JK. Decreased beta-adrenergic receptors in rat brain after chronic administration of the selective serotonin uptake inhibitor fluoxetine. Psychopharmacology (Berl) 1988;94:141-3.
27. Pile A, Enna SJ. Supersensitive beta-adrenergic receptors are down-regulated in rat brain by mianserin administration. J Neural Transm 1987;70:71-9.
28. Asakura M, Tsukamoto T, Kubota H, Imafuku J, Ino M, Nishizaki J, Sato A, Shinbo K, Hasegawa K. Role of serotonin in the regulation of beta-adrenoceptors by antidepressants. Eur J Pharmacol 1987;141:95-100.
29. Klysner R, Geisler A. Rapid downregulation of cerebral β-adrenoceptors by combined treatment with imipramine and mianserin. In: Amsterdam JD, ed. Advances in neuropsychiatry and psychopharmacology, vol. 2: refractory depression. New York: Raven Press, 1991:109-13.
30. Willner P. The ability of antidepressant drugs to desensitize β-receptors is inversely correlated with their clinical potency. J Affect Disord 1984;7:53-8.
31. Stahl S. 5HT2A receptors and pharmacotherapy: is serotonin receptor down-regulation linked to the mechanism of action of antidepressant drugs? Psychopharmacol Bull 1994;30:39-43.
32. Roth BL, Ciaranello RD. Chronic mianserin treatment decreases 5-HT2 receptor binding without altering 5-HT2 receptor mRNA levels. Eur J Pharmacol 1991;207:169-72.
33. Blier P, de Montigny C, Tardif D. Effects of two antidepressant drugs mianserin and indalpine on the serotonergic system: single-cell studies in the rat. Psychopharmacology (Berl) 1984;84:242-9.
34. Friedman E, Cooper TB, Dallob A. Effects of chronic antidepressant treatment on serotonin receptor activity in mice. Eur J Pharmacol 1983;89:69-76.
35. Mongeau R, Blier P, de Montigny C. In vivo electrophysiological evidence for tonic activation by endogenous noradrenaline of alpha 2-adrenoceptors on 5-hydroxytryptamine terminals in the rat hippocampus. Naunyn Schmiedebergs Arch Pharmacol 1993; 347:266-72.
36. De Boer T, Nefkens F, Van Helvoirt A, Van Delft AML. Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther 1996;277:852-60.